QuidelOrtho (NASDAQ:QDEL) Issues FY 2026 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.650-0.900 for the period, compared to the consensus EPS estimate of 1.850. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.7 billion.

QuidelOrtho Trading Down 24.8%

QuidelOrtho stock traded down $4.04 during mid-day trading on Friday, hitting $12.28. 4,888,567 shares of the stock were exchanged, compared to its average volume of 1,173,664. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. QuidelOrtho has a 12 month low of $9.92 and a 12 month high of $35.58. The firm’s fifty day simple moving average is $15.75 and its two-hundred day simple moving average is $17.55. The stock has a market capitalization of $837.37 million, a price-to-earnings ratio of -0.80 and a beta of 0.68.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.78%. The company had revenue of $630.90 million for the quarter, compared to analyst estimates of $618.72 million. During the same period in the prior year, the firm posted $0.12 EPS. The company’s quarterly revenue was up 2.8% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Analysts forecast that QuidelOrtho will post 1.87 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on QDEL. Citigroup upped their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Monday, June 15th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research report on Friday, July 17th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of QuidelOrtho in a research note on Monday, June 29th. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $13.62.

Trending Headlines about QuidelOrtho

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: QuidelOrtho reported second-quarter adjusted earnings of $0.13 per share, compared with analysts’ expected loss of approximately $0.05 per share and $0.12 per share a year earlier. Revenue of $630.9 million also exceeded the roughly $618.7 million consensus estimate. QuidelOrtho Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Quarterly revenue increased approximately 3% year over year, driven primarily by growth in the Labs and Point-of-Care businesses. Excluding China, revenue growth was stronger at 6%, suggesting underlying demand was healthier outside the Chinese market. QuidelOrtho Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Management’s earnings-call discussion focused on operating performance across its diagnostics portfolio and the updated outlook for the remainder of 2026. Investors are likely to scrutinize whether Labs and Point-of-Care growth can offset weaker conditions in China and support a sustained recovery. QuidelOrtho Q2 2026 Earnings Call Transcript
• Negative Sentiment: QuidelOrtho lowered its full-year 2026 guidance to $0.65–$0.90 in EPS and $2.5–$2.6 billion in revenue. Those ranges are substantially below analyst expectations of about $1.85–$1.87 EPS and $2.7 billion in revenue, signaling weaker profitability and sales than previously anticipated. QuidelOrtho Second Quarter Results

Hedge Funds Weigh In On QuidelOrtho

Institutional investors have recently made changes to their positions in the stock. Invesco Ltd. grew its holdings in QuidelOrtho by 87.0% during the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock worth $85,604,000 after buying an additional 1,352,503 shares in the last quarter. Newtyn Management LLC lifted its stake in QuidelOrtho by 58.3% during the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock valued at $79,515,000 after acquiring an additional 994,332 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in QuidelOrtho by 101.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,755,401 shares of the company’s stock valued at $50,134,000 after acquiring an additional 883,077 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in QuidelOrtho by 7.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after acquiring an additional 819,908 shares during the last quarter. Finally, State Street Corp boosted its holdings in QuidelOrtho by 23.3% during the 2nd quarter. State Street Corp now owns 2,700,940 shares of the company’s stock worth $77,841,000 after acquiring an additional 510,291 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.